FBLG — FibroBiologics, Inc. Dilution Risk Tracker

FibroBiologics, Inc. (FBLG) carries a DilutionScore of 92/100, placing it in the Critical dilution risk tier — the highest category tracked by DilutionWatch. Companies at this level typically have active capital-raising programs, compressed cash runway, or a combination of dilution vectors that together represent meaningful downside risk to share count. As of July 13, 2026, this score reflects real-time data pulled directly from SEC EDGAR filings.

The most significant dilution vector for FBLG is its shelf registration capacity of $50.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. FBLG has an active ATM (at-the-market) program with $6.2M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event.

DilutionWatch tracks over 25 SEC filing types for FBLG in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for FBLG alongside comparable critical-risk stocks. Not financial advice — this analysis is for informational purposes only.